化合物J-113863 T11699

Product Introduction
Bioactivity


英文名: J-113863

描述: J-113863 是选择性的 CCR1 (CD18)拮抗剂，有抗炎作用，对人和小鼠 CCR1受体的 IC50值分别为 0.9 和 5.8 nM。它是人 CCR3的强效拮抗剂，还是小鼠 CCR3的弱效拮抗剂，IC50分别为 0.58 和 460 nM。

体外活性: The chemotaxis of the following cells were inhibited by J-113863. Modified Vaccinia virus Ankara (MVA) but not MVA and vaccinia virus (VACV) infected MH-S cells increase the expression of the CXCR2 acting chemokine CXCL2. MH-S cells constitutively produce CCL2 and CCR1 acting chemokines CCL3, CCL5 and CCL9. Consequently, supernatants of mock treated and virus infected MH-S cells induce chemotaxis of murine promyelocyte MPRO cells and human monocytic THP-1 cells at the same level. However, supernatants of MVA infected MH-S cells significantly increase chemotaxis of the CCR2 deficient human monocytic cell line U-937.

体内活性: J-113863 treatment improves paw inflammation and joint damage, and dramatically decreases cell infiltration into joints in arthritic mice.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 6.56 mg/mL (10 mM)


关键字: CCR | Inhibitor | inhibit | rheumatoid | CCR1 | CCR3 | J 113863 | CC chemokine receptor | Chemotaxis | J-113863 | collagen | arthritis | J113863 | CD18 | anti-inflammatory

相关产品: Vicriviroc maleate | BMS CCR2 22 | BI-6901 | C-021 | RS102895 hydrochloride | SB 328437 | MK-0812 Succinate | Vercirnon | Aplaviroc | CCR2 antagonist 5

相关库: Anti-Aging Compound Library | Cytokine Inhibitor Library | Immuno-Oncology Compound Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Inhibitor Library | Anti-Fibrosis Compound Library | Chemokine Inhibitor Library | NO PAINS Compound Library | Bioactive Compound Library

化合物J-113863 T11699信息由TargetMol中国为您提供，如您想了解更多关于化合物J-113863 T11699报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途